Breast Cancer

Maura Dickler, MD, discusses findings from the recent phase II study exploring abemaciclib as a single agent in patients with HR-positive breast cancer, along with an upcoming phase III trial looking at combination strategies.

Joanne L. Blum, MD, PhD, discusses the design and phase III results from the ABC trials, and what impact the encouraging findings could have in patients with HER2-negative breast cancer.

Henry M. Kuerer, MD, PhD, professor of Surgery, PH and Fay Etta Robinson Distinguished Professor in Research, Breast Surgical Oncology, executive director, Breast Programs, director, Breast Surgical Oncology Fellowship Training Program, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the challenges associated with treating patients with ductal carcinoma in situ (DCIS).

Anees B. Chagpar, MD, associate professor of Surgery (Oncology) and director of The Breast Center at Smilow Cancer Hospital at Yale-New Haven, discusses how surgical oncologists should approach the treatment of a patient with HER2-positive breast cancer.

Kevin S. Hughes, MD, co-director, Avon Comprehensive Breast Evaluation Center, medical director, Bermuda Cancer Genetics and Risk Assessment Clinic, Harvard Medical School, Massachusetts General Hospital, discusses treatment with radiation therapy for patients with ER-positive breast cancer.

A marketing authorization application has been submitted to the European Medicines Agency for neratinib as a potential extended adjuvant therapy for patients with HER2-positive early stage breast cancer following 12 months of trastuzumab.

Hyman B. Muss, MD, School of Medicine, University of North Carolina (UNC)-Chapel Hill, Breast Cancer, Geriatric Oncology Program, Mary Jones Hudson Distinguished Professorship in Geriatric Oncology, discusses assessing treatment response in patients with metastatic breast cancer.

Lisa A. Carey, MD, comments on the recent I-SPY 2 and KRISTINE findings, the I-SPY 2 program as a whole, and the work ahead in the neoadjuvant landscape of HER2-positive breast cancer.

During the past 2 years, there have been a number of advancements in the treatment of metastatic breast cancer that include the development of novel agents and new strategies in several disease settings, resulting in improved outcomes for patients.

After years of anticipation, biosimilar versions of the most widely administered monoclonal antibodies in oncology care are moving closer to fruition for the US market, starting with a new form of trastuzumab (Herceptin).

Maura N. Dickler, MD, Memorial Sloan Kettering Cancer Center, discusses the results of the single-arm MONARCH 1 trial, which examined the efficacy of the CDK4/6 inhibitor abemaciclib in heavily pretreated patients with refractory, hormone-receptor (HR)–positive, HER2-negative advanced breast cancer.

Adding the CDK 4/6 inhibitor palbociclib (Ibrance) to letrozole reduced the risk of disease progression by 42% compared with letrozole alone in patients with ER-positive, HER2-negative advanced or metastatic breast cancer.